Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Opioid Overdose
Interventions: Opioid Rapid Resonse System (ORRS) training, Non-active opioid overdose response training; Behavioral
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 100 Years
Enrollment: 773 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity, Methamphetamine Use Disorder
Interventions: Tirzepatide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Posttraumatic Stress Disorder
Interventions: Written Exposure Therapy, Cognitive Processing Therapy; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma, Brain Cancer, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, MGMT-Unmethylated Glioblastoma, MGMT-Methylated Glioblastoma
Interventions: Ruxolitinib, Temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Miami, Florida • New York, New York

Conditions: Bipolar Disorder
Interventions: ABBV-932, Itraconazole; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Alamitos, California • Grayslake, Illinois

Conditions: Cardiovascular Diseases, Cardiac Rehabilitation, Transition of Care
Interventions: T2CR Intervention, Usual Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Anxiety, Anxiety Depression, Worry, Depression, Rumination - Thoughts
Interventions: Be Specific, Be Kind, Be Present, Break Habit, Psychoeducation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Imperial, California

Conditions: Posttraumatic Stress Disorder
Interventions: Building Resilience after Childhood Emergencies (BRACE); Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 8 Years to 13 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Childhood Obesity
Interventions: H2GO!; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 9 Years and older
Enrollment: 820 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myelodysplastic Syndromes
Interventions: lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 31
States / cities: Scottsdale, Arizona • Tucson, Arizona • Rancho Mirage, California + 22 more

Conditions: Phantom Limb Pain After Amputation, Lower Limb Amputation, Upper Limb Amputation, Phantom Pain, Chronic Pain
Interventions: Operant Conditioning with Peripheral Stimulation, Control Group with Peripheral Stimulation Only; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Albany, New York

Conditions: Human Immunodeficiency Virus Infections
Interventions: Efavirenz 600mg, Boosted Lexiva; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Background care, Placebo, dalcetrapib; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 45 Years and older
Enrollment: 2,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 121
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 112 more

Conditions: Diabetes, Hyperglycemia, Hypoglycemia
Interventions: The Sensing Device; Device
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 19 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Renal Failure, Kidney Disease, Coronary Artery Disease
Interventions: IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 5,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Palo Alto, California + 32 more

Conditions: Cancer, Lung, Metastasis
Interventions: Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR); Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Interventions: Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Adolescent
Interventions: Guys/Girls Opt for Activities for Life (GOAL); Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 10 Years to 14 Years
Enrollment: 935 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • East Lansing, Michigan

Conditions: Post Traumatic Stress Disorder
Interventions: Written Exposure Therapy (WISE), Non-emotional Writing; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Gainesville, Florida • Indianapolis, Indiana • Worcester, Massachusetts + 3 more

Conditions: Post-Concussion Syndrome
Interventions: Craniosacral Therapy; Other
Lead sponsor: Special Therapies, Inc.; Other
Eligibility: 14 Years to 90 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Renal Cell Carcinoma, Hypertension, Melanoma, Cancer
Interventions: Ambulatory Blood Pressure Measurement; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Thyroid Nodule, Thyroid Goiter, Ablation
Interventions: nPulse Vybrance Percutaneous Electrode System; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Sarasota, Florida • New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 low dose, Placebo BI 10773 high dose, BI 10773 high dose, Placebo BI 10773 low dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 7,064 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 170
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more

Conditions: Musculoskeletal Pain, Analgesia, Adverse Event
Interventions: Ketorolac Injection 15 mg, Ketorolac Injection 60 mg; Drug
Lead sponsor: William Beaumont Army Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: El Paso, Texas

Search by objective public record fields.

Opioid Rapid Response System: Naloxone Training in Communities

Tirzepatide for Obesity and Meth Use Disorder

Written Exposure Therapy for Posttraumatic Stress Disorder

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder

Transition to Cardiac Rehabilitation (T2CR) to Address Barriers of Multimorbidity and Frailty

Calming Minds Study

Building Resilience After Childhood Emergencies (BRACE)

A Cluster Randomized Trial of the H2GO! Program

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Operant Conditioning of Sensory Brain Responses to Reduce Phantom Limb Pain in People With Limb Amputation

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events

Prevention of Serious Adverse Events Following Angiography

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Guys/Girls Opt for Activities for Life Trial (GOAL) to Increase Young Adolescents' Physical Activity and Healthy Eating

Written Exposure Therapy to Improve Lives After Stress Exposure

Craniosacral Therapy for Concussion Symptoms

Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Intramuscular Ketorolac at Two Single-Dose Regimens